CALT vs. STOK, GHRS, OLMA, PHAT, ZYME, PHAR, IGMS, LYEL, ORIC, and AVBP
Should you be buying Calliditas Therapeutics AB (publ) stock or one of its competitors? The main competitors of Calliditas Therapeutics AB (publ) include Stoke Therapeutics (STOK), GH Research (GHRS), Olema Pharmaceuticals (OLMA), Phathom Pharmaceuticals (PHAT), Zymeworks (ZYME), Pharming Group (PHAR), IGM Biosciences (IGMS), Lyell Immunopharma (LYEL), ORIC Pharmaceuticals (ORIC), and ArriVent BioPharma (AVBP). These companies are all part of the "pharmaceutical preparations" industry.
Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Stoke Therapeutics (NASDAQ:STOK) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, community ranking, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.
2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are owned by insiders. Comparatively, 11.3% of Stoke Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Calliditas Therapeutics AB (publ) presently has a consensus target price of $34.00, indicating a potential upside of 65.53%. Stoke Therapeutics has a consensus target price of $20.57, indicating a potential upside of 79.19%. Given Stoke Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Stoke Therapeutics is more favorable than Calliditas Therapeutics AB (publ).
Stoke Therapeutics received 74 more outperform votes than Calliditas Therapeutics AB (publ) when rated by MarketBeat users. Likewise, 72.99% of users gave Stoke Therapeutics an outperform vote while only 60.47% of users gave Calliditas Therapeutics AB (publ) an outperform vote.
Calliditas Therapeutics AB (publ) has a beta of 1.5, indicating that its stock price is 50% more volatile than the S&P 500. Comparatively, Stoke Therapeutics has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500.
Calliditas Therapeutics AB (publ) has higher revenue and earnings than Stoke Therapeutics. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Stoke Therapeutics had 31 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 37 mentions for Stoke Therapeutics and 6 mentions for Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ)'s average media sentiment score of 0.32 beat Stoke Therapeutics' score of 0.08 indicating that Calliditas Therapeutics AB (publ) is being referred to more favorably in the media.
Stoke Therapeutics has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -38.72%. Stoke Therapeutics' return on equity of -65.47% beat Calliditas Therapeutics AB (publ)'s return on equity.
Summary
Stoke Therapeutics beats Calliditas Therapeutics AB (publ) on 11 of the 18 factors compared between the two stocks.
Get Calliditas Therapeutics AB (publ) News Delivered to You Automatically
Sign up to receive the latest news and ratings for CALT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Calliditas Therapeutics AB (publ) Competitors List
Related Companies and Tools
